icumedical

human connections

ICU Medical, Inc.
Investor Presentation
(NASDAQ:ICUI)

January 2015





Forward Looking Statement

- > Any statement concerning Management's expectation with respect to future results is a forward looking statement based upon the best information currently available to Management and assumptions Management believes are reasonable, but Management does not intend the statement to be a representation as to future results.
- > Future results are subject to risks and uncertainties, including the risk factors described in the Company's filings with the Securities and Exchange Commission, which include those in the Form 10-K for the year ended December 31, 2013. Actual results in the future may differ materially from Management's current expectations.



ICU Medical At-a-Glance

> We are a \$300M+ revenue publicly traded global medical device company (NASDAQ: ICUI) developing differentiated products and technologies addressing unmet clinical needs in three market segments:



Infusion Therapy

Industry leading needlefree IV connector technology and custom IV sets

2014 Est Revenues* \$214 M 70% of Total

*December 2014 estimate



Oncology

Needlefree closed system transfer devices and automated compounders for safely handling hazardous drugs

> 2014 Est Revenues* \$37 M 12% of Total



Critical Care

Systems and disposables for accurate, reliable hemodynamic monitoring

2014 Est Revenues* \$54 M 18% of Total



Reasons to Consider Investing


- High percentage of sticky, recurring revenues
- Positioned for near-term EPS and cash flow growth and long-term revenue growth
- International growth opportunities are increasing due to adoption of technology and evolving medical standards
- Manufacturing scale and capital investment offer high barriers to entry
- Pristine balance sheet with cash on hand equal to more than 1/3 of Company enterprise value
- Improved profits during decline of a single 30% customer and improving free cash flow with lower CapEx requirements
- > Intensity and focus after a long public transition period and exit from a founder-led organization

Overview	
> Share Price (01/09/15)	\$84.15
> Shares Outstanding (9/30/14)	15.3M
> Market Capitalization (01/09/15)	\$1,293M
> Cash & Investments (12/31/14 Est)	\$345M
> Enterprise Value (01/09/15)	\$948M
> FY15 Adj EBITDA Guidance*	\$85.0M
> FY15 Adj EBITDA Multiple (01/09/	15) 11.2X
> Average Volume (3 Months)	~159K



^{*}December 2014 estimate

ICU Medical Revenues & Gross Margin





Value Creation Drivers

- Implemented operational improvements across variety of cost drivers to yield at least \$10 million of SG&A improvements in FY15 versus FY14
- > Focus on improved domestic commercial execution
- > Continue international investments to drive growth in proprietary IV connectors and custom sets market
- Tailwinds and policy-making driving oncology
- > World-class low cost manufacturing with excess capacity and most investments made
- Strong balance sheet for both capital deployment and return of capital
- > Re-engaged management team with incentives aligned with shareholder interests



2015 Guidance: Adjusted EBITDA \$85 Million OEM customer expected to be down -5% to - 10%




IV Therapy Solutions

MORE THAN 90% of hospitalized patients receive IV therapy during their hospital stay. For this, ICU Medical provides:

The world's most complete line of needlefree IV connectors



The world's most complete line of standard and custom IV sets



IV Connector & Sets \$2 Billion+ Worldwide Market



Connector Design Drives Clinical Value

Clinically-proven design features work together to provide a safe and effective microbial barrier helping keep patients safer from bloodstream infections—a major non-reimbursable expense to hospitals

> Three distinct connectors with a unique set of clinical benefits unmatched in the industry

A single clinical protocol can be used used with all patient populations, minimizing clinical training and in-servicing while helping provide maximum patient safety throughout the hospital

Neutron®

Prevents reflux and reduces occlusions, for use on long-dwelling central and PICC IV lines.



NanoClave®

Minimal flush volumes for managing fluids and keeping neonatal and pediatric patients safe.



MicroClave® Clear

Broad applications thoughout the hospital, incorporating market-leading infection control properties.



Flat, swabbable surface with Split-septum

CDC-preferred design features for connectors.

Straight fluid path

for clearing blood and blood residual with low flush volumes.

Minimal residual volume

allows for lower flush volumes.


Clear housing

permits visual confirmation of flush after use with medications or blood.



IV Therapy Solutions

Custom and Standard Set Capabilities. Broadly deploying our market-leading connector technology in a wide range of stock and custom IN sets and kits.





IV Therapy Revenues





Critical Care Solutions

Hemodynamic Monitoring Systems and Disposables Used in Acute Care Settings to Measure a Patient's Cardiovascular Status > Specialized area of monitoring—we do not compete with multiparameter monitoring companies > Razor/razor blade business model, ICU Medical disposables used in hemodynamic monitoring include: > Pressure Transducers > Closed Blood Sampling Systems > Advanced Sensor Catheters > Pulmonary Artery Catheters Central Venous Catheters & > Minimally Invasive Cardiac Oximetry Catheters **Output Sensors** 0 = 6 System Disposables



Critical Care Business Overview



Created Critical Care Division with senior-level management and enhanced marketing/sales support in July 2014

> > Margin improvement initiatives: performing worldwide pricing and SKU rationalization, acquired Australian distributor

> Growth initiatives: US channel development, OEM and strategic partnership activities


Investing \$10 million+ in R&D, including patient monitoring platform (2015 launch)

- > Innovative form-factor for maximum clinical flexibility. Weight <10 lbs.
- > Wireless connectivity
- > All major hemodynamic parameters measured and displayed
- > Invasive and minimally invasive inputs





Critical Care Revenues





Oncology Solutions

> The world's most comprehensive IV medication safe handling systems designed to keep pharmacists, nurses, and patients safe from exposure to hazardous drugs used in chemotherapy during preparation, transportation, administration, and disposal.



ChemoClave®

Needlefree Closed Systems and Closed System Transfer Devices

Cost-effectively keep yourself safe from exposure to hazardous drugs while maintaining drug sterility.



ChemoLock™

Needlefree Closed System Transfer Device (CSTD)

Minimize exposure to hazardous drugs and maximize medication safety while ensuring compliance from beginning to end.

Closed System Transfer Devices (CSTDs) Drive the Oncology Business.

ICU Medical is the only company to offer two complete needlefree CSTD systems with two distinct value propositions.



Diana is an Early-Stage Differentiated Product.

User-controlled automated compounding system that uses our ChemoClave to facilitate closed fluid transfer. Limited release

Diana™

Automated Drug Compounding System

Accurately, safely, and efficiently prepare IV medications with user-controlled automated compounding technology.



Positive Market Trends Driving CSTDs

Growing Awareness, Mounting Support/Evidence for the need for CSTD's

> State Legislation

- WA, CA, NC (passed)
- MD(filed, pending)

> USP Chapter Update

- USP <800> Proposed New Chapter
- > Includes Administration
- > CSTD *shall* be used during administration

> FDA ONB Code

New Product Classification Code for CSTDs







CALIFORNIA STATE LEGISLATURE

ASSEMBLY BILL

No. 1202

Introduced by Assembly Member Skinne February 22, 2013

An act to add Section 144.8 to the Labor Code, relating to occupational safety and health standards.

LEGISLATIVE COUNSEL'S DIGE

AB 1202, as introduced, Skinner. Occupational safety and healt

somistives incorross origin.

Under existing law, the Occupational Safety and Health Standards
Board within the Department of Industrial Relations promulgates
occupational safety and bealth standards for the state, including
standards dealing with toxic materials and harmful physical agents.

**Robinshi or vance variation from regiments in a virtual or distribution in virtual and a constraint of the handling of antinosphate, and other hazardoon foreign, as defined, in health care facilities and the series of the series. The bill reconstraint of the constraint of the con



SENATE BILL REPORT SR 5594

As Reported by Serate Committee On:

Labor, Commerce & Consumer Protection, Feb lifle: An act relating to handling of hazardous drugs.

Brief Description: Regulating the handling of hexistens drugs.

Sponsory: Senators Kohl-Weller, Keiser, Prentier, Conway, Kline and Mur

Committee Activity: Labor, Commerce & Consumer Protection: 1/31/11, 2/07/11, 2/10

(NY N. WARREL)

Majority Report: That Substitute Senate Bill No. 5594 be substituted therefor, and

Signed by Senators Kohl-Welles, Chair, Corway, Vice Chair, Keiser and Kline.

Signed by Senators Holmquist Newbry, Ranking Minority Member, King, Assista

Staff: Ecith Rice (786-74

Buckground: Astinophistic deups are chemotherapy agents that control or kill cancer or li-Drags used in the treatment of cancer are cytonosic (destructive to cells within the body) be very used, lover chamselve as dividing or offs does a residence offs.

Workers may be exposed to a hazardous drug at many points during its manufacture temport, distribution, receipt, storage, preparation, and administration, as well as during wante handling and opagement maintenance and repair. All workers involved in these

Exposure to these drugs in the workplace has been associated with acute and short-term reactions, as well as long-term effects. Reports range from Adverdated and coular effects to flu-like symptoms, sere throst, chronic cough, infections, dizziness, eye intlation, and




Oncology Revenues





ICU Medical Global Manufacturing



- > World-class molding, automation, and custom set assembly processes
- > 1,900+ operations employees worldwide
- > 100% paperless production
- > Capital expenditures declining, most capacity/automation investments have been made



Ensenada, MX 250,000 Square Feet Custom Set Manufacturing



Slovakia 80,000 Square Feet Custom Set Manufacturing










Management Team


- > Vivek Jain CEO, 11 months, CareFusion/Cardinal, JP Morgan
- > Scott Lamb CFO, 11 years, GE, various start-ups
- > Alison Burcar VP/GM Infusion Systems, 19 years
- > Steve Riggs VP Operations, 22 years
- > Greg Pratt VP Sales, 18 years
- > Tom McCall VP/GM Critical Care, 4 years, Masimo, Welch-Allyn



Financials









icumedical

human connections

ICU Medical, Inc.
Investor Presentation
(NASDAQ:ICUI)

January 2015



